Gene study aims to solve heart drug mystery
NCT ID NCT07408427
First seen Feb 16, 2026 · Last updated May 14, 2026 · Updated 14 times
Summary
This study looks at why the heart medication mavacamten works better for some people with hypertrophic cardiomyopathy (a thickened heart muscle) than others. Researchers will check if a person's specific gene that causes the condition, and their natural ability to process drugs, affects the medicine's performance. The goal is to personalize treatment based on genetics, involving 140 adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Manchester Centre for Genomic Medicine (MCGM)
Multiple Locations, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.